(HNR1) Hannover Rück SE - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0008402215
Stock: Property, Casualty, Life, Health, Reinsurance
Total Rating 27
Risk 39
Buy Signal -0.37
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.21% |
| Yield on Cost 5y | 6.98% |
| Yield CAGR 5y | 18.92% |
| Payout Consistency | 71.3% |
| Payout Ratio | 55.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.1% |
| Relative Tail Risk | -3.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.13 |
| Alpha | -5.04 |
| Character TTM | |
|---|---|
| Beta | -0.010 |
| Beta Downside | 0.023 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.34% |
| CAGR/Max DD | 0.64 |
Description: HNR1 Hannover Rück SE December 17, 2025
Hannover Rück SE (XETRA:HNR1) is a global reinsurer operating through Property & Casualty and Life & Health segments, covering lines such as agricultural, aviation, natural catastrophe, cyber, marine, critical illness, longevity and Takaful across Europe, the US, Asia and other regions.
Beyond traditional treaty reinsurance, the firm offers structured solutions-including insurance-linked securities, reserve- and solvency-relief financing, and monetisation of embedded value-leveraging its position as a subsidiary of Talanx AG. The company, founded in 1966 and renamed in 2013, remains headquartered in Hanover, Germany.
In 2023 Hannover Rück reported a combined ratio of 94.5% and a net profit of €2.5 bn, with a return on equity of roughly 13%, reflecting strong underwriting discipline amid rising climate-related loss trends and a low-interest-rate environment that pressures investment income. For a deeper quantitative view, you might explore the ValueRay platforms detailed risk metrics.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 2.47b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.02 > 1.0 |
| NWC/Revenue: 4680 % < 20% (prev 215.9%; Δ 4464 % < -1%) |
| CFO/TA 0.08 > 3% & CFO 5.31b > Net Income 2.47b |
| Net Debt (-1.26b) to EBITDA (3.42b): -0.37 < 3 |
| Current Ratio: 91.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (120.5m) vs 12m ago -0.07% < -2% |
| Gross Margin: 91.99% > 18% (prev 0.37%; Δ 9161 % > 0.5%) |
| Asset Turnover: 1.78% > 50% (prev 35.49%; Δ -33.71% > 0%) |
| Interest Coverage Ratio: 6.07 > 6 (EBITDA TTM 3.42b / Interest Expense TTM 147.8m) |
Altman Z'' 6.30
| A: 0.83 (Total Current Assets 59.11b - Total Current Liabilities 648.9m) / Total Assets 70.35b |
| B: 0.17 (Retained Earnings 12.03b / Total Assets 70.35b) |
| C: 0.01 (EBIT TTM 897.3m / Avg Total Assets 70.32b) |
| D: 0.20 (Book Value of Equity 11.28b / Total Liabilities 57.45b) |
| Altman-Z'' Score: 6.30 = AAA |
Beneish M 1.00
| DSRI: 20.72 (Receivables 1.66b/1.60b, Revenue 1.25b/24.95b) |
| GMI: 0.40 (GM 91.99% / 37.21%) |
| AQI: 0.74 (AQ_t 0.16 / AQ_t-1 0.21) |
| SGI: 0.05 (Revenue 1.25b / 24.95b) |
| TATA: -0.04 (NI 2.47b - CFO 5.31b) / TA 70.35b) |
| Beneish M-Score: 11.79 (Cap -4..+1) = D |
What is the price of HNR1 shares?
As of February 08, 2026, the stock is trading at EUR 248.40 with a total of 82,397 shares traded.
Over the past week, the price has changed by +4.02%, over one month by -0.80%, over three months by -0.56% and over the past year by -1.29%.
Over the past week, the price has changed by +4.02%, over one month by -0.80%, over three months by -0.56% and over the past year by -1.29%.
Is HNR1 a buy, sell or hold?
Hannover Rück SE has no consensus analysts rating.
What are the forecasts/targets for the HNR1 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 283.9 | 14.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 282.1 | 13.6% |
HNR1 Fundamental Data Overview February 03, 2026
Market Cap USD = 33.99b (28.80b EUR * 1.1801 EUR.USD)
P/E Trailing = 11.6659
P/E Forward = 10.7875
P/S = 1.0163
P/B = 2.3898
P/EG = 1.1172
Revenue TTM = 1.25b EUR
EBIT TTM = 897.3m EUR
EBITDA TTM = 3.42b EUR
Long Term Debt = 4.19b EUR (from longTermDebt, last quarter)
Short Term Debt = 99.5m EUR (from shortTermDebt, last fiscal year)
Debt = 4.19b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.26b EUR (from netDebt column, last quarter)
Enterprise Value = 31.73b EUR (28.80b + Debt 4.19b - CCE 1.26b)
Interest Coverage Ratio = 6.07 (Ebit TTM 897.3m / Interest Expense TTM 147.8m)
EV/FCF = 5.98x (Enterprise Value 31.73b / FCF TTM 5.31b)
FCF Yield = 16.72% (FCF TTM 5.31b / Enterprise Value 31.73b)
FCF Margin = 424.7% (FCF TTM 5.31b / Revenue TTM 1.25b)
Net Margin = 197.7% (Net Income TTM 2.47b / Revenue TTM 1.25b)
Gross Margin = 91.99% ((Revenue TTM 1.25b - Cost of Revenue TTM 100.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.45 (Enterprise Value 31.73b / Total Assets 70.35b)
Interest Expense / Debt = 0.52% (Interest Expense 21.7m / Debt 4.19b)
Taxrate = 5.14% (36.8m / 716.6m)
NOPAT = 851.2m (EBIT 897.3m * (1 - 5.14%))
Current Ratio = 91.09 (Total Current Assets 59.11b / Total Current Liabilities 648.9m)
Debt / Equity = 0.35 (Debt 4.19b / totalStockholderEquity, last quarter 12.00b)
Debt / EBITDA = -0.37 (Net Debt -1.26b / EBITDA 3.42b)
Debt / FCF = -0.24 (Net Debt -1.26b / FCF TTM 5.31b)
Total Stockholder Equity = 11.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.51% (Net Income 2.47b / Total Assets 70.35b)
RoE = 21.03% (Net Income TTM 2.47b / Total Stockholder Equity 11.74b)
RoCE = 5.63% (EBIT 897.3m / Capital Employed (Equity 11.74b + L.T.Debt 4.19b))
RoIC = 6.61% (NOPAT 851.2m / Invested Capital 12.88b)
WACC = 5.19% (E(28.80b)/V(32.99b) * Re(5.88%) + D(4.19b)/V(32.99b) * Rd(0.52%) * (1-Tc(0.05)))
Discount Rate = 5.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.02%
[DCF Debug] Terminal Value 86.74% ; FCFF base≈5.59b ; Y1≈5.83b ; Y5≈6.70b
Fair Price DCF = 1660 (EV 198.88b - Net Debt -1.26b = Equity 200.14b / Shares 120.6m; r=5.90% [WACC]; 5y FCF grow 4.47% → 2.90% )
EPS Correlation: 70.35 | EPS CAGR: 15.85% | SUE: 0.14 | # QB: 0
Revenue Correlation: -26.80 | Revenue CAGR: -5.93% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=6.06 | Chg30d=+0.167 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=22.88 | Chg30d=-0.070 | Revisions Net=-2 | Growth EPS=+7.1% | Growth Revenue=+4.6%
P/E Trailing = 11.6659
P/E Forward = 10.7875
P/S = 1.0163
P/B = 2.3898
P/EG = 1.1172
Revenue TTM = 1.25b EUR
EBIT TTM = 897.3m EUR
EBITDA TTM = 3.42b EUR
Long Term Debt = 4.19b EUR (from longTermDebt, last quarter)
Short Term Debt = 99.5m EUR (from shortTermDebt, last fiscal year)
Debt = 4.19b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.26b EUR (from netDebt column, last quarter)
Enterprise Value = 31.73b EUR (28.80b + Debt 4.19b - CCE 1.26b)
Interest Coverage Ratio = 6.07 (Ebit TTM 897.3m / Interest Expense TTM 147.8m)
EV/FCF = 5.98x (Enterprise Value 31.73b / FCF TTM 5.31b)
FCF Yield = 16.72% (FCF TTM 5.31b / Enterprise Value 31.73b)
FCF Margin = 424.7% (FCF TTM 5.31b / Revenue TTM 1.25b)
Net Margin = 197.7% (Net Income TTM 2.47b / Revenue TTM 1.25b)
Gross Margin = 91.99% ((Revenue TTM 1.25b - Cost of Revenue TTM 100.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.45 (Enterprise Value 31.73b / Total Assets 70.35b)
Interest Expense / Debt = 0.52% (Interest Expense 21.7m / Debt 4.19b)
Taxrate = 5.14% (36.8m / 716.6m)
NOPAT = 851.2m (EBIT 897.3m * (1 - 5.14%))
Current Ratio = 91.09 (Total Current Assets 59.11b / Total Current Liabilities 648.9m)
Debt / Equity = 0.35 (Debt 4.19b / totalStockholderEquity, last quarter 12.00b)
Debt / EBITDA = -0.37 (Net Debt -1.26b / EBITDA 3.42b)
Debt / FCF = -0.24 (Net Debt -1.26b / FCF TTM 5.31b)
Total Stockholder Equity = 11.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.51% (Net Income 2.47b / Total Assets 70.35b)
RoE = 21.03% (Net Income TTM 2.47b / Total Stockholder Equity 11.74b)
RoCE = 5.63% (EBIT 897.3m / Capital Employed (Equity 11.74b + L.T.Debt 4.19b))
RoIC = 6.61% (NOPAT 851.2m / Invested Capital 12.88b)
WACC = 5.19% (E(28.80b)/V(32.99b) * Re(5.88%) + D(4.19b)/V(32.99b) * Rd(0.52%) * (1-Tc(0.05)))
Discount Rate = 5.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.02%
[DCF Debug] Terminal Value 86.74% ; FCFF base≈5.59b ; Y1≈5.83b ; Y5≈6.70b
Fair Price DCF = 1660 (EV 198.88b - Net Debt -1.26b = Equity 200.14b / Shares 120.6m; r=5.90% [WACC]; 5y FCF grow 4.47% → 2.90% )
EPS Correlation: 70.35 | EPS CAGR: 15.85% | SUE: 0.14 | # QB: 0
Revenue Correlation: -26.80 | Revenue CAGR: -5.93% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=6.06 | Chg30d=+0.167 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=22.88 | Chg30d=-0.070 | Revisions Net=-2 | Growth EPS=+7.1% | Growth Revenue=+4.6%